Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Hyperlipidemia Market?

The market size of hyperlipidemia has seen consistent growth in the past few years. Its expansion is projected to mode from $20.24 billion in 2024 to reach a value of $21.03 billion in 2025, with a compound annual growth rate (CAGR) of 3.9%. The growth experienced in the historic period is a result of increased demand for potent treatments, geographical extension, heightened public consciousness of hyperlipidemia, and tobacco usage.

What Growth Rate Is Forecasted for the Hyperlipidemia Market by 2029?

In the coming years, the hyperlipidemia market is predicted to experience consistent growth, reaching $24.3 billion in 2029 at a Compound Annual Growth Rate (CAGR) of 3.7%. This projected growth during the forecast period can be linked to the increasing demand for hyperlipidemia medicines, global health movements, an aging demographic, preventive healthcare, and early interventions. Upcoming trends within the forecast period include innovative therapies, the use of digital health technologies for managing hyperlipidemia, the application of biomarkers in diagnosing and treating hyperlipidemia, along with the research and development initiatives within pharmaceutical treatments.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

Which Key Companies Are Shaping the Future of the Hyperlipidemia Market?

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

Which Factors Are Driving Demand in the Hyperlipidemia Industry?

The escalation in chronic disorders like heart disease is anticipated to stimulate the hyperlipidemia market’s expansion. Heart diseases encompass any diseases affecting the heart’s performance. Hyperlipidemia treatment aids those struggling with heart disease by attenuating the threat of heart attacks, averting strokes, promoting endothelial function, and diminishing the requirement for invasive procedures. In September 2024, data from the British Heart Foundation—a UK-based heart research charity—demonstrated that around 7.6 million people were affected by heart and circulation diseases in the UK, including roughly 4 million men and 3.6 million women. These diseases account for approximately 27% of all deaths in the UK, which equals more than 170,000 deaths per year, or around 480 deaths daily. This amounts to one death every three minutes. Therefore, the rise in chronic disorders like heart disease fuels the expansion of the hyperlipidemia market. Smoking-related health hazards are expected to be a key driver for the hyperlipidemia market. The escalating trend of smoking is predicted to further boost the hyperlipidemia market. Tobacco smoking, which involves burning tobacco, inhaling the resultant smoke for its taste, and allowing its elements to enter the bloodstream, is connected to common risk factors for hyperlipidemia which include obesity and insulin resistance. These factors potentially lead to dyslipidemia, identified by irregular lipid levels, potentially resulting in hyperlipidemia eventually. As per data from Statistics Canada in July 2022, a 5.8% surge in cigarette production was reported compared to June 2021, with total cigarette sales hitting 1.4 billion in June 2022. Therefore, the increasing trend of smoking propels the hyperlipidemia market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12873&type=smp

How Is the Hyperlipidemia Market Segmented by Several Divisions?

The hyperlipidemia market covered in this report is segmented –

1) By Type: Familial, Acquired

2) By Treatment: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Other Treatment

3) By Route of Administration: Oral, Parenteral

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH), Familial Combined Hyperlipidemia, Familial Dysbetalipoproteinemia

2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia, Secondary Hyperlipidemia, Drug-Induced Hyperlipidemia

What are the Emerging Market Trends Driving the Growth of the Hyperlipidemia Industry?

Leading firms in the hyperlipidemia marketplace such as the US-based biotechnology enterprise, Regeneron Pharmaceuticals, Inc., are making strides in the development of innovative advanced low-density lipoprotein cholesterol-lowering products to maintain their market standing. Notably, in March 2024, the U.S. Food & Drug Administration (FDA) gave its authorization for the use of Praluent (alirocumab) Injection, produced by Regeneron Pharmaceuticals. This novel drug is considered a significant progression in tackling heterozygous familial hypercholesterolemia (HeFH) in young patients aged 8 or older. It provides a dedicated solution to control threateningly elevated levels of low-density lipoprotein cholesterol (LDL-C). Backed by Phase 3 trial findings which showed a 31% decrease in LDL-C levels with scheduled administering, it showcases a trustworthy safety record, similar to adult counterparts. The drug is also the pioneer therapy to target the genetically-verified PCSK9 protein, marking a significant landmark in the therapy of heart-related ailments. All these characteristics make Praluent a key alternative for regulating high cholesterol in children diagnosed with HeFH.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Which Regions Are Driving Growth in the Hyperlipidemia Market?

North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12873

This Report Delivers Insight On:

1. How big is the hyperlipidemia market, and how is it changing globally?

2. Who are the major companies in the hyperlipidemia market, and how are they performing?

3. What are the key opportunities and risks in the hyperlipidemia market right now?

4. Which products or customer segments are growing the most in the hyperlipidemia market?

5. What factors are helping or slowing down the growth of the hyperlipidemia market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model